Dual inhibition of topoisomerase I and tubulin polymerization by BPR0Y007, a novel cytotoxic agent

Biochemical Pharmacology

Volumn 65, Issue 12, 2003, Pages 2009-2019

  Chang, Jang Yang ^a   Hsieh, Hsing Pang ^a   Pan, Wen Yu ^a   Liou, Jing Ping ^a   Bey, Shian Jy ^a   Chen, Li Tzong ^a,b   Liu, Jin Fen ^a   Song, Jen Shin ^a  

^a NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Dual inhibitor; Topoisomerase I; Tubulin

Indexed keywords

2,5 BIS(4 HYDROXY 3 METHOXYBENZYLIDENE)CYCLOPENTANONE; BPR 0Y007; CAMPTOTHECIN; COLCHICINE; CONGOCIDINE; CYTOTOXIC AGENT; DNA TOPOISOMERASE INHIBITOR; DOXORUBICIN; DYE; ETOPOSIDE; INTERCALATING AGENT; PACLITAXEL; UNCLASSIFIED DRUG; VINCRISTINE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BINDING SITE; CANCER CELL CULTURE; CELL CYCLE; CELL CYCLE G2 PHASE; CELL LINE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CROSS RESISTANCE; DNA CLEAVAGE; DNA DENATURATION; DNA STRAND BREAKAGE; DRUG BINDING; DRUG MECHANISM; DRUG POTENCY; ENZYME INHIBITION; ENZYME SPECIFICITY; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; MACROMOLECULE; MICROTUBULE ASSEMBLY; OBSERVATION; PRIORITY JOURNAL;

EID: 0037716242     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(03)00197-7     Document Type: Article

References (34)

1. Gellert M. DNA topoisomerases. Annu. Rev. Biochem. 50:1981;879-910.
2. Wang J.C. DNA topoisomerases. Annu. Rev. Biochem. 54:1985;665-697.
3. Wang J.C. DNA topoisomerases: why so many? J. Biol. Chem. 266:1991;6659-6662.
4. Champoux J.J. Evidence for an intermediate with a single-strand break in the reaction catalyzed by the DNA unwinding enzyme. Proc. Natl. Acad. Sci. U.S.A. 73:1976;3488-3491.
5. Champoux J.J. DNA is linked to the rat liver DNA nicking-closing enzyme by a phosphodiester bond to tyrosine. J. Biol. Chem. 256:1981;4805-4809.
6. Tsao Y.P., Russo A., Nyamuswa G., Sibler R., Liu L.F. Interaction between the replication fork and topoisomerase I-DNA cleavable complexes. Study in a cell-free SV40 DNA replication system. Cancer Res. 53:1993;1-8.
7. Hsiang Y.H., Lihou M.G., Liu L.F. Arrest of replication forks by drug-stabilized topoisomerase-I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res. 49:1989;5077-5082.
8. D'Arpa P., Beardmore C., Liu L.F. Involvement of nucleic acid synthesis in cell killing mechanisms of topoisomerase poisons. Cancer Res. 50:1990;6919-6924.
9. Goldwasser F., Bae I., Valenti M., Torres K., Pommier Y. Topoisomerase-I-related parameters and camptothecin activity in the colon carcinoma cell lines from the National Cancer Institute anticancer screen. Cancer Res. 55:1995;2116-2121.
10. Morris E.J., Geller H.M. Induction of neuronal apoptosis by CPT, an inhibitor of DNA topoisomerase I: evidence for cell cycle-independent toxicity. J. Cell Biol. 134:1996;757-770.
11. Vanhoefer U., Harstrick A., Achterrath W., Cao S., Seeber S., Rustum Y.M. Irinotecan in the treatment of colorectal cancer: clinical review. J. Clin. Oncol. 19:2001;1501-1518.
12. Gore M., ten Bokkel Huinink W., Carmichael J., Gordon A., Davidson N., Coleman R., Spaczynski M., Heron J.F., Bolis G., Malmstrom H., Malfetano J., Scarabelli C., Vennin P., Ross G., Fields S.Z. Clinical evidence for topotecan-paclitaxel non-cross-resistance in ovarian cancer. J. Clin. Oncol. 19:2001;1893-1900.
13. Sardjiman S.S., Reksohadiprodjo M.S., Hakim L., van der Good H., Timmerman H. 1,5-Diphenyl-1,4-pentadiene-3-ones and cyclic analogues as antioxidative agents. Synthesis and structure-activity relationship. Eur. J. Med. Chem. 32:1997;625-630.
14. Ferguson P.J., Fisher M.H., Stephensen J., Li D.H., Zhou B.S., Cheng Y.C. Combined modalities of resistance in etoposide-resistant human KB cell lines. Cancer Res. 48:1988;5956-5964.
15. Biedler D.R., Chang J.Y., Zhou B.S., Cheng Y.C. Camptothecin resistance involving steps subsequent to the formation of protein-linked DNA breaks in human camptothecin-resistant KB cell lines. Cancer Res. 56:1996;345-353.
16. Chang J.Y., Liu J.F., Juang S.H., Liu T.W., Chen L.T. Novel mutation of topoisomerase I in rendering cells resistant to camptothecin. Cancer Res. 62:2002;3716-3721.
17. Goodwin C.J., Holt S.J., Downes S., Marshall N.J. Microtubule tetrazolium assays: a comparison between two new tetrazolium salts, XTT and MTS. J. Immunol. Methods. 179:1995;95-103.
18. Liu L.F., Miller K.G. Eukaryotic DNA topoisomerases, two forms of type I DNA topoisomerases from HeLa cell nuclei. Proc. Natl. Acad. Sci. U.S.A. 78:1981;3487-3491.
19. Nelson E.M., Tewey K.M., Liu L.F. Mechanism of antitumor drugs: poisoning of mammalian DNA topoisomerase II on DNA by an antitumor drug, m-AMSA. Proc. Natl. Acad. Sci. U.S.A. 81:1984;1361-1365.
20. Rowe T.C., Chen G.L., Hsiang Y.H., Liu L.F. DNA damage by antitumor acridines mediated by mammalian DNA topoisomerase II. Cancer Res. 46:1986;2021-2026.
21. Camilloni G., Della Seta F., Negri R., Grazia Ficca A., Di Mauro E. Structure of RNA polymerase II promoters: conformational alterations and template properties of circularized Saccharomyces cerevisae GAL1-GAL10 divergent promoters. EMBO J. 5:1986;763-771.
22. Montecucco A., Pedrali-Nov G., Spadari S., Zanolin E., Ciarrocchi G. DNA unwinding and inhibition of T4 DNA ligase by anthracyclins. Nucleic Acids Res. 16:1988;3907-3918.
23. Yamori T., Matsunaga A., Sata S., Yamazaki K., Komi A., Ishizu K., Mita I., Edatsugi H., Matsuba Y., Takezawa K., Nakanishi O., Kohno H., Nakajima Y., Komatsu H., Andoh T., Tsuruo T. Potent antitumor activity of MS-247, a novel DNA minor groove binder evaluated by an in vitro and in vivo human cancer cell line panel. Cancer Res. 59:1999;4042-4049.
24. Jett JH. Mathematical analysis of DNA: histograms from asynchronous and synchronous cell populations. In: Lutz D, editor. Pulse cytophotometry. Brussels, Belgium: European Press; 1978. p. 93-102.
25. Finlay G.J., Baguley B.C., Wilson W.R. A semiautomated microculture method for investigating exponentially growing carcinoma cells. Anal. Biochem. 139:1984;272-277.
26. 6G ]AATTCGCG complexed with Hoechst 33358 or 33342 EMBO J. 11:1992;225-232.
27. Robinson H., Gao Y.G., Bauer C., Roberts C., Switzer C., Wang A.H. 2′-Deoxyisoguanosine adopts more than one tautomer to form base pairs with thymidine observed by high-resolution crystal structure analysis. Biochemistry. 17:1998;10897-10905.
28. Tabernero L., Verdaguer N., Coll M., Fita I., van der Marel G.A., van Boom J.H., Rich A., Aymami J. Molecular structure of the A-tract DNA dodecamer d(CGCAAATTTGCG) complexed with minor groove binding drug netropsin. Biochemistry. 32:1993;8403-8410.
29. Pourquier P., Pommier Y. Toposimerase I-mediated DNA damage. Adv. Cancer Res. 80:2000;189-216.
30. Chen A.Y., Yu C., Gatto B., Liu L.F. DNA minor groove-binding ligands: a different class of mammalian DNA topoisomerase I inhibitors. Proc. Natl. Acad. Sci. U.S.A. 90:1993;8131-8135.
31. Poddevin B., Riou J.F., Lavelle F., Pommier Y. Dual topoisomerase I and II inhibition by intoplicine (RP-60645), a new antitumor agent in early clinical trials. Mol. Pharmacol. 44:1993;767-774.
32. Udea K., Cardarelli C., Gottesman M.M., Pastan I. Expression of a full-length cDNA for the human "MDR1" gene confers resistance to colchicine, doxorubicin, and vinblastine. Proc. Natl. Acad. Sci. U.S.A. 84:1987;3004-3008.
33. Horwitz SB, Liao LL, Greenberger L. Mode of action of taxol and characterization of multidrug-resistant cell lines resistant to taxol. In: Kessel D, editor. Resistance to antineoplastic drugs. Boca Raton, FL: CRS Press; 1989. p. 109-26.
34. Kuo M.L., Huang T.S., Lin J.K. Curcumin, an antioxidant and anti-tumor promoter, induces apoptosis in human leukemia cells. Biochim. Biophys. Acta. 1317:1996;95-100.